Dolutegravir superior to standard dose efavirenz in WHO analysis
1 October 2016. Related: Antiretrovirals.
Antiretrovirals
Dual therapy with dolutegravir + 3TC keep viral load undetectable: 48 week results from PADDLE study
1 August 2016. Related: Conference reports, Antiretrovirals.
Once-daily raltegravir at last available: 48 week results from ONCEMRK study
1 August 2016. Related: Conference reports, Antiretrovirals.
Dual long-acting cabotegravir plus rilpivirine injections: 48-week results from LATTE-2
1 August 2016. Related: Conference reports, Antiretrovirals.
Dolutegravir is superior to boosted atazanavir in women in the ARIA study
1 August 2016. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy.
Pharmacokinetics of antiretrovirals comparable to that in non-pregnant women from three weeks after delivery
1 August 2016. Related: Conference reports, Antiretrovirals, Pregnancy.
The antiretroviral pipeline 2016
14 July 2016. Related: Pipeline report, Antiretrovirals.
Fit for purpose: antiretroviral treatment optimisation 2016
14 July 2016. Related: Pipeline report, Fit for purpose, Antiretrovirals.
The paediatric antiretroviral pipeline
14 July 2016. Related: Pipeline report, Antiretrovirals, Paediatric care.
Preventive technologies: antiretroviral and vaccine development
14 July 2016. Related: Pipeline report, Antiretrovirals, HIV prevention and transmission, Vaccines and microbicides.
HIV positive people on ART have impaired alveolar immunity
1 June 2016. Related: Conference reports, Antiretrovirals, Coinfections and complications.
Studies of new generic $300 HepC combination of ravidasvir and sofosbuvir for low-income countries
1 June 2016. Related: Conference reports, Antiretrovirals, Hepatitis coinfection.
No effect of tenofovir on infant bone mineral content in African study
1 June 2016. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
Use of modelling to predicting paediatric dosing of long acting antiretrovirals
1 June 2016. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
START substudies: increased quality of life from earlier treatment but no impact on vascular function or cardiovascular markers
1 June 2016. Related: Conference reports, Antiretrovirals, Coinfections and complications.
FTC/TAF dual-nuke approved in the US and Europe
1 June 2016. Related: Antiretrovirals.
Paediatric labeling expanded, and additional tablet strengths for FTC/TDF
1 June 2016. Related: Antiretrovirals.
Dual long-acting injections of cabotegravir plus rilpivirine: 32-week results from LATTE-2 study
22 March 2016. Related: Conference reports, Antiretrovirals.
New NRTI MK-8591 (EFdA): weekly oral dosing and once-yearly slow-release dosing has potential for HIV treatment and PrEP
22 March 2016. Related: Conference reports, Antiretrovirals.
Similar viral load reductions at week 4 when dolutegravir is used with 2- or 3-drug initial ART
22 March 2016. Related: Conference reports, Antiretrovirals.
48-week results for NNRTI doravirine compared to efavirenz
22 March 2016. Related: Conference reports, Antiretrovirals.
Countries with lower HIV prevalence have lower ART coverage
22 March 2016. Related: Conference reports, Antiretrovirals, Treatment access.
Nigerian herbal medicines widely used by HIV positive people can contain antiretrovirals
22 March 2016. Related: Conference reports, Antiretrovirals.
EU adopts positive opinion on dual formulation of F/TAF
22 March 2016. Related: Antiretrovirals.
New TAF-containing fixed dose combination approved in the US
22 March 2016. Related: Antiretrovirals.
BMS sells pipeline compounds to ViiV Healthcare
1 February 2016. Related: Antiretrovirals.
EU provide positive approval for generic lopinavir/ritonavir
1 February 2016. Related: Antiretrovirals.
Further results using dolutegravir monotherapy: urgent need for controlled studies
1 February 2016. Related: Antiretrovirals, Treatment strategies.
Potential economic impact of dolutegravir/3TC dual therapy
1 February 2016. Related: Antiretrovirals, Treatment strategies.
Remarkable results with dolutegravir monotherapy
1 December 2015. Related: Conference reports, Antiretrovirals, Vaccines and microbicides.
First-line ART with dolutegravir plus 3TC: 24-week early results
1 December 2015. Related: Conference reports, Antiretrovirals, Treatment strategies.
Achieving viral suppression with HIV multi-drug resistance: peg-interferon and valaciclovir as part of rescue therapy
1 December 2015. Related: Conference reports, Antiretrovirals, Treatment strategies, Drug resistance.
Substituting lopinavir/ritonavir with efavirenz in children on stable ART
1 December 2015. Related: Conference reports, Antiretrovirals, Paediatric care.
Tenofovir alafenamide (TAF) approved – but only as part of a fixed dose combination
1 December 2015. Related: Antiretrovirals.
No transmission of integrase-resistant HIV seen in California cohort
1 October 2015. Related: Conference reports, Antiretrovirals, HIV prevention and transmission, Drug resistance.
Doubled hypogonadism rate in middle-aged men with HIV: fat is a factor
1 October 2015. Related: Conference reports, Antiretrovirals, Side effects.
Reducing efavirenz dose is unlikely to overcome interaction with levonorgestrel
1 October 2015. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy, PK and drug interactions.
Doravirine and cabotegravir do not affect the pharmacokinetics of oral contraceptives
1 October 2015. Related: Conference reports, Antiretrovirals, Women's health, PK and drug interactions.
Dolutegravir placental transfer moderate in ex vivo model
1 October 2015. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
FDA approve additional weight band dosing for children using atazanavir powder
1 October 2015. Related: Antiretrovirals, Paediatric care.
Four reasons IAS 2015 will be a milestone HIV conference: a personal view
1 August 2015. Related: Conference reports, Antiretrovirals, Treatment strategies, HIV prevention and transmission.
Starting HIV treatment at high CD4 counts protects against both AIDS and non-AIDS events: overall and in subgroup analyses of START study
1 August 2015. Related: Conference reports, Antiretrovirals, Treatment strategies.
Pipeline ARVs at IAS 2015: doravirine, BMS-955176 and BMS-663068
1 August 2015. Related: Conference reports, Antiretrovirals.
Rapid implementation of the 2013 WHO ART guidelines
1 August 2015. Related: Conference reports, Antiretrovirals, Guidelines.
Rilpivirine/FTC/TAF becomes the third TAF-based fixed dose combination submitted for US approval
1 August 2015. Related: Antiretrovirals.
The antiretroviral pipeline 2015
17 July 2015. Related: Pipeline report, Antiretrovirals.
Fit for purpose: antiretroviral treatment optimisation 2015
17 July 2015. Related: Pipeline report, Fit for purpose, Antiretrovirals.
The Pediatric Antiretroviral Pipeline
17 July 2015. Related: Pipeline report, Antiretrovirals, Paediatric care.
BHIVA pregnancy audit 2013 to 2014
1 June 2015. Related: Conference reports, Antiretrovirals, Pregnancy.
Primary HIV infection and early use of ART
1 June 2015. Related: Conference reports, Antiretrovirals.
Rectal STIs and viral load in HIV positive men on and off ART
1 June 2015. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Other short reports from BHIVA:
1 June 2015. Related: Conference reports, Antiretrovirals, Paediatric care, Basic science and immunology.
Elvitegravir in children and adolescents
1 June 2015. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
PK of ARVs in pregnancy: rilpivirine, etravirine and raltegravir
1 June 2015. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
Pharmacokinetics in pregnancy: darunavir/r and etravirine
1 June 2015. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
Low prolactin and high 20alpha-HSD might contribute to ART-associated progesterone deficits in pregnancy
1 June 2015. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy.
Pregnancy rates among women using ART and hormonal contraceptives in Kenya
1 June 2015. Related: Conference reports, Antiretrovirals, Pregnancy.
Gender difference in virological response to ART
1 June 2015. Related: Conference reports, Antiretrovirals, Women's health.
Generic dolutegravir submitted to FDA for tentative approval
1 June 2015. Related: Antiretrovirals, Treatment access.
EMA approves coformulated atazanavir/cobicistat
1 June 2015. Related: Antiretrovirals.
Dual F/TAF formulation under evaluation by EMA
1 June 2015. Related: Antiretrovirals.
Pipeline ART: tenofovir alafenamide (TAF)
24 March 2015. Related: Conference reports, Antiretrovirals.
Pipeline ART: maturation inhibitors and an attachment inhibitor
24 March 2015. Related: Conference reports, Antiretrovirals.
PrEP reduced HIV risk by at least 86% in PROUD: no transmissions likely from people taking meds
24 March 2015. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
FDA approves fixed dose darunavir/cobicistat
24 March 2015. Related: Antiretrovirals.